If you track everything, starting a GLP-1 medication is a new stream of data — and one of the first things you'll notice is that your resting heart rate on the watch doesn't sit still. Before you read too much into a single trend line, it helps to understand what that number can and can't tell you.

Why resting heart rate moves at all

Resting heart rate (RHR) is one of the more meaningful signals a wrist wearable captures, because it reflects the balance between your two branches of the autonomic nervous system — the sympathetic ("accelerator") and parasympathetic ("brake"). A lower RHR generally tracks with better cardiorespiratory fitness and higher vagal tone, while a rising RHR can reflect stress, poor sleep, dehydration, illness, alcohol, or simply an under-recovered day [1].

That last point matters for a newcomer to GLP-1 therapy. Early on, appetite and food intake often drop, fluid intake can drop with it, and gastrointestinal side effects are common. Each of those can nudge RHR up or down independent of anything happening at the level of the heart itself. In other words, the watch is measuring your whole physiology, not just the drug.

Resting heart rate reference zones (general adult context)
Typical resting range ≤90Elevated for many adults ≤100

bpm · marker = Common example baseline

Source: [1] Resting Heart Rate and Cardiovascular Disease (review of RHR as a physiologic and prognostic marker)

What the cardiovascular data on GLP-1 medications actually shows

Semaglutide belongs to a class called GLP-1 receptor agonists. Across large trials, drugs in this class have been associated with a small average increase in heart rate — typically in the range of a few beats per minute — alongside reductions in blood pressure [2][3]. The mechanism isn't fully settled, but it's thought to involve GLP-1 receptor activity affecting the sinoatrial node and autonomic signaling [2].

A "few beats per minute" is a population average, not a personal forecast. Some people see no change on their wearable; others notice a modest, gradual uptick that stabilizes. What providers care about is the *pattern* — direction, size, and whether it comes with symptoms — not an isolated reading.

It's also worth knowing the broader cardiovascular context. In the SELECT trial, semaglutide was studied in adults with overweight or obesity and established cardiovascular disease who did not have diabetes; the trial examined major adverse cardiovascular events [4]. This is educational context about what has been studied — not a claim about what will happen for you, and not a reason to start or stop anything on your own.

What the class-level heart rate signal looks like
~2–4 bpmTypical average RHR change reported for GLP-1 receptor agonistspopulation average, not a personal forecast
↓Direction of the blood pressure associationmodest average reductions reported alongside HR changes

Source: [2] GLP-1 receptor agonists and heart rate: mechanistic and clinical review

Reading your own trend without over-reading it

Here's the engineer's trap: treating a noisy signal as if every wiggle means something. A few principles keep the data honest:

  • Look at baselines, not days. A 7-day or 14-day rolling median filters out the night you slept badly or the afternoon you had three coffees. One high morning reading is weather, not climate.
  • Confounders are everywhere. Dehydration from reduced intake, a recent workout, alcohol, a cold, and anxiety all move RHR. During the early adjustment period, intake changes are especially common.
  • Symptoms outrank numbers. A stable-looking RHR with new chest pain, fainting, or a racing sensation is more important than a modestly elevated RHR that you feel nothing from.
  • Wrist optical sensors have limits. They're good for trends, less reliable for capturing brief rhythm irregularities. Consumer devices are not diagnostic tools [5].
How to read your own trend, not the noise
1Capture baseline1–2 weeks of RHR before any change
2Track the median7–14 day rolling, not single days
3Note confounderssleep, fluids, alcohol, illness
4Flag symptomspalpitations or dizziness → contact a provider

Source: [1] Resting Heart Rate and Cardiovascular Disease (review of RHR as a physiologic and prognostic marker), [5] FDA: General Wellness — Policy for Low Risk Devices (guidance on consumer wellness devices)

The cardiac patterns a provider actually reviews

When an independent provider reviews someone on a GLP-1 medication, RHR is one input among several. The things that tend to get attention include:

  • A large or sustained rise, rather than a small, stable one.
  • Palpitations or an irregular pulse, which can prompt a check for arrhythmias such as atrial fibrillation — something a single wrist RHR number won't diagnose.
  • Symptoms of dehydration or low fluid volume, since persistent vomiting or diarrhea can drive heart rate up and warrant attention on their own.
  • Blood pressure trends alongside heart rate, because the two are read together, not in isolation.
  • Your personal history — existing cardiovascular conditions, other medications, and your baseline fitness.

This is exactly why the number alone doesn't tell the story. A resting heart rate of 68 means one thing for a lifelong runner and another for someone whose baseline was 58 last month. Context, direction, and symptoms are what turn data into a picture.

What a newcomer can reasonably do

If you're the type who wants a baseline before anyone recommends a thing — that instinct is the right one. A useful approach is to capture your RHR trend for a couple of weeks *before* any intervention, so you have a personal reference line rather than guessing later. Pair that with the labs and vitals a provider would want to see, and bring the actual data to the conversation.

And if you notice a change you can't explain — a steady climb, new palpitations, lightheadedness, or anything that worries you — that's a reason to contact a provider promptly rather than debugging it solo in a spreadsheet.

This article is educational and is not medical advice, diagnosis, or a recommendation to take any specific medication. Whether any medication is appropriate is a decision made by an independent licensed provider based on your full history.

Where Velri fits

Velri is a technology and coordination company — it does not provide medical care. What Velri can do is help organize the parts that usually live in separate silos: coordinating a baseline lab panel, connecting you with an independent, licensed provider who reviews your results and history, and — only if that provider decides a prescription is appropriate — coordinating with an independent licensed pharmacy. A prescription is never guaranteed; that decision belongs to the provider.

For readers weighing compounded options: compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality. Compounded products are not equivalent to or interchangeable with any FDA-approved brand-name drug. Availability varies by state.

The goal is simple — get the numbers first, have someone qualified explain what they mean, and make any decision from there.